Stockscreener 앱 받기
8.55
0.12%
-0.010
시간 외 거래:
8.55
전일 마감가:
$8.56
열려 있는:
$8.49
하루 거래량:
1.13M
Relative Volume:
0.62
시가총액:
$1.11B
수익:
$727.33M
순이익/손실:
$-108.03M
주가수익비율:
-10.13
EPS:
-0.844
순현금흐름:
$-21.78M
1주 성능:
-6.04%
1개월 성능:
-25.33%
6개월 성능:
+2.52%
1년 성능:
-21.42%
1일 변동 폭
$8.43
$8.65
1주일 범위
$8.43
$9.38
52주 변동 폭
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
명칭
Neogenomics Inc
전화
(239) 768-0600
주소
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
8.55 | 1.11B | 727.33M | -108.03M | -21.78M | -0.844 |
|
TMO
Thermo Fisher Scientific Inc
|
495.72 | 185.77B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
195.06 | 138.05B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
600.52 | 47.68B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
115.42 | 32.62B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
297.54 | 29.39B | 3.17B | 642.63M | 516.49M | 10.77 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-07-29 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | 개시 | Guggenheim | Neutral |
| 2025-04-30 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-12-10 | 개시 | Jefferies | Buy |
| 2024-05-01 | 재개 | Craig Hallum | Buy |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-08-21 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-02-24 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-02-01 | 업그레이드 | Needham | Hold → Buy |
| 2022-08-26 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-08-22 | 다운그레이드 | Needham | Buy → Hold |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-03-29 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-29 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 재개 | Stephens | Overweight |
| 2021-12-16 | 개시 | Cowen | Outperform |
| 2021-11-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-02-25 | 재개 | Needham | Buy |
| 2021-02-25 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-12-11 | 재개 | BTIG Research | Buy |
| 2020-10-28 | 재확인 | Needham | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-08-28 | 개시 | Guggenheim | Buy |
| 2020-07-29 | 재확인 | Needham | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Buy |
| 2020-04-21 | 재개 | Stephens | Overweight |
| 2020-03-02 | 재개 | Craig Hallum | Buy |
| 2020-02-28 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 재확인 | Needham | Buy |
| 2019-05-01 | 재확인 | Needham | Buy |
| 2019-03-29 | 재확인 | Needham | Buy |
| 2019-01-03 | 개시 | Needham | Buy |
| 2018-10-24 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 개시 | Leerink Partners | Outperform |
| 2018-05-02 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2017-08-24 | 개시 | Gabelli & Co | Buy |
| 2016-12-15 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Neogenomics Inc 주식(NEO)의 최신 뉴스
NeoGenomics at Leerink Conference: Strategic Growth Focus - Investing.com
Investment Recap: Is NeoGenomics Inc gaining market share2026 Volatility Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Insider Sell: Can NeoGenomics Inc deliver alphaMarket Activity Report & Expert Verified Movement Alerts - baoquankhu1.vn
GW&K Investment Management LLC Cuts Stock Position in NeoGenomics, Inc. $NEO - MarketBeat
Royce & Associates LP Sells 860,000 Shares of NeoGenomics, Inc. $NEO - MarketBeat
Vanguard Group Inc. Has $107.34 Million Stock Position in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics, Inc. $NEO Shares Sold by Segall Bryant & Hamill LLC - MarketBeat
NeoGenomics (NEO) accounting chief granted new options and RSUs - Stock Titan
Equity awards expand NeoGenomics (NEO) EVP Olivo’s stock-based pay - Stock Titan
NeoGenomics (NEO) COO receives new stock option and RSU grants - Stock Titan
Major equity grants to NeoGenomics (NEO) CEO Anthony P. Zook - Stock Titan
NeoGenomics at TD Cowen Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
NeoGenomics at TD Cowen Conference: Strategic Growth Insights - Investing.com South Africa
A Look At NeoGenomics (NEO) Valuation After The RaDaR ST Assay Launch - simplywall.st
NeoGenomics Stock Price Drops Below 200-Day Average - National Today
NeoGenomics (NASDAQ:NEO) Stock Price Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
NeoGenomics (NEO) CFO Abhishek Jain granted options and RSUs - Stock Titan
Oversold Conditions For NeoGenomics (NEO) - Nasdaq
NEO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NEO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Earnings are out: How did SWFL companies perform? - Naples Daily News
Natera, NeoGenomics Unit End Patent Suit Over Lung Cancer Test - Bloomberg Law News
3 Reasons to Avoid NEO and 1 Stock to Buy Instead - Yahoo Finance
(NEO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tu - PharmiWeb.com
NeoGenomics Launches RaDaR ST Molecular Residual Disease Test - marketscreener.com
NeoGenomics, Inc. Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types - marketscreener.com
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types - The Joplin Globe
NeoGenomics, Inc. Trade Ideas — FWB:NG9 - TradingView
NeoGenomics outlines $793M–$801M 2026 revenue target as RaDaR ST and PanTracer initiatives gain traction - MSN
NeoGenomics (NEO) COO logs RSU vesting and tax share withholding - Stock Titan
Equity moves for NeoGenomics (NASDAQ: NEO) CFO Jeffrey Sherman - Stock Titan
NeoGenomics (NEO) EVP nets new shares from RSU vesting and tax withholding - Stock Titan
NeoGenomics (NEO) CAO converts RSUs to stock and withholds shares for taxes - Stock Titan
NeoGenomics, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Financial Indicators - Markets Mojo
5 Insightful Analyst Questions From NeoGenomics's Q4 Earnings Call - Finviz
NeoGenomics, Inc. (NEO) Stock Analysis: A 47% Upside Potential in the Healthcare Diagnostics Sector - DirectorsTalk Interviews
5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call - Yahoo Finance
NeoGenomics (NEO) Q4 2025 Earnings Call Transcript - AOL.com
NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness - Yahoo Finance
NeoGenomics, Inc. $NEO Shares Bought by White Pine Capital LLC - MarketBeat
NeoGenomics, Inc. $NEO Stock Holdings Lifted by Aberdeen Group plc - MarketBeat
Short Squeeze: What is the PEG ratio of Brookdale Senior Living IncStock Surge & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO) - Finviz
NeoGenomics to Participate in the 20th Annual Needham Virtual Healthcare Conference - ACCESS Newswire
Why is NeoGenomics Inc. stock going upM&A Rumor & Free High Accuracy Swing Entry Alerts - mfd.ru
UBS Maintains Hold on NeoGenomics, Inc. (NEO) on Feb 18, 2026 - Meyka
Needham & Company LLC Forecasts Strong Price Appreciation for NeoGenomics (NASDAQ:NEO) Stock - Defense World
NeoGenomics Q4 Earnings Call Highlights - Defense World
NeoGenomics Faces High-Stakes Risk as Test Reliability and Diagnostic Errors Threaten Reputation and Legal Exposure - TipRanks
Neogenomics Inc (NEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.17%
0.64%
자본화:
|
볼륨(24시간):